The orthopedic device, intended for spinal stabilization, received a Traditional 510(k) clearance, confirming its substantial equivalence to predicate devices.
Rivarp Medical Pvt., Ltd. has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Kentrospine Viktr-MIS® Pedicle Screw System. The decision, dated September 27, 2026, classifies the system as substantially equivalent, enabling its marketing in the United States.
The Kentrospine Viktr-MIS® Pedicle Screw System falls under product code NKB, indicating its classification as a pedicle screw spinal system. This device is regulated as a Class II medical device under regulation number 888.3070, which covers spinal intervertebral body fixation orthosis.
Device Overview and Regulatory Pathway
The Kentrospine Viktr-MIS® is designed for spinal stabilization, consistent with the intended use of pedicle screw systems. Its 510(k) clearance was processed as a Traditional 510(k), a common pathway for devices demonstrating substantial equivalence to a legally marketed predicate device.
The FDA's Orthopedic Advisory Committee oversees devices in this category, ensuring that new devices meet safety and efficacy standards through comparison with established technologies. Rivarp Medical submitted a summary statement for this clearance, indicating the submission provided sufficient information for the agency to determine substantial equivalence without requiring a full summary of safety and effectiveness data.
Market Implications
The clearance positions Rivarp Medical to enter or expand within the competitive spinal implant market. Pedicle screw systems are widely used in spinal fusion surgeries to provide stability while bone grafts heal. The 'MIS' designation in the product name suggests an intended application in minimally invasive surgical procedures, an area of growing interest due to potential benefits such as reduced recovery times and smaller incisions.
Specific clinical data supporting the device's performance, pricing, and launch strategy have not been publicly disclosed by Rivarp Medical. The company will now proceed with commercialization plans for the U.S. market, subject to standard post-market surveillance requirements for Class II devices.
